Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Q1 Revenues Fall by Nearly Half as Losses Mount

NEW YORK, May 9 (GenomeWeb News) - Tripos today reported a 43-percent slide in first-quarter revenues amid mounting losses.


Tripos' revenues slipped to $8.5 million from $15 million in Q1 2005.


The company attributed the slide to the completion of a four-year, $90 million file-enrichment project with Pfizer that Tripos said in November would not be renewed.


"This required a reduction in force, which primarily affected Tripos Discovery Research, in Bude, England, and a corresponding reorganization of operating activities in our laboratories," John McAlister, president and CEO of Tripos, said in a statement. "Our first-quarter 2006 financial results reflect the interruptions and inefficiencies in our operations while we implemented the reorganization."


The company spent $2.8 million on R&D in the first quarter of 2006, compared to $1.9 million in Q1 2005.


Tripos reported a net loss of $3.7 million, or $0.36 per diluted share, compared to a net loss of $19,000, or $0.00 per diluted share, in the year-ago period.


As of March 31, Tripos had $5.2 million in cash and cash equivalents on hand.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.